Outcome of therapy‐related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis

Itonaga, Hidehiro; Kida, Michiko; Hamamura, Atsushi; Uchida, Naoyuki; Ozawa, Yukiyasu; Fukuda, Takahiro; Ueda, Yasunori; Kataoka, Keisuke; Katayama, Yuta; Ota, Shuichi; Matsuoka, Ken‐ichi; Kondo, Tadakazu; Eto, Tetsuya; Kanda, Junya; Ichinohe, Tatsuo; Atsuta, Yoshiko; Miyazaki, Yasushi; Ishiyama, Ken

doi:10.1002/hon.2991

Cited by 6 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a propensity score matched analysis comparing t‐MDS with de novo MDS (d‐MDS) by Itonaga et al, patients with t‐MDS had similar 3‐year CIR (32.8% vs. 33%, respectively; p = .983) but higher 3‐year TRM (30.9% vs. 19%, respectively; p = .005) and worse OS (40% vs. 50%, respectively; p = .032). In multivariate analysis, four factors were identified as important to be associated with worse survival, including age ≥55 years, poor cytogenetic risk group, ECOG 2–4 and a shorter interval from diagnosis to transplantation less than 8 months 91 …”

Section: Transplantation For Patients With Therapy Related Mdsmentioning

confidence: 99%

Allogeneic stem cell transplantation for patients with myelodysplastic syndromes

2022

View full text Add to dashboard Cite

Myelodysplastic syndromes (MDS) are a heterogenous group of clonal hematopoietic stem cell neoplasms primarily affecting older persons, associated with dysplastic changes of bone marrow cells, peripheral cytopenias, and various risk of leukemic transformation. Although treatment with several drugs has shown improved disease control, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment for MDS. The number of patients receiving a transplant, as well as survival, have increased past years because of the use of reduce-intensity conditioning regimens (RIC) as well as the use of haploidentical donors for transplantation. With treatment-related mortality as main limitation, pre-transplant evaluation is essential to assess risks for this older group of patients. In a recent randomized study, allo-HSCT with RIC for patients >50 years old with higher-risk MDS demonstrated superiority in survival compared with hypomethylating agents. Genetic mutations have been shown to significantly impact treatment outcomes including after transplant. Recently, a transplant-specific risk score (which includes age, donor type, performance status, cytogenetic category, recipient's cytomegalovirus status, percentage of blasts, and platelet count) has shown superiority in transplantation outcome prediction, compared with previous scoring systems. Survival remains low for most patients with TP53 mutations and novel treatment strategies are needed, such as administration of natural killer cells post-transplant, as there is no clear evidence that maintenance therapy after transplantation can improve outcomes.

show abstract

Section: Transplantation For Patients With Therapy Related Mdsmentioning

confidence: 99%

Allogeneic stem cell transplantation for patients with myelodysplastic syndromes

2022

View full text Add to dashboard Cite

show abstract

Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical relatives in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia: a propensity score analysis of a nationwide database

et al. 2023

View full text Add to dashboard Cite

The clinical outcomes of haploidentical stem cell transplantation (haplo-HSCT) for patients with therapy-related myelodysplastic syndrome: comparable to de novo myelodysplastic syndrome

Tang,

Wang,

Wang

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

Therapy-related myelodysplastic syndrome (t-MDS) is defined as a complication in patients with cancer following exposure to chemotherapy and/or radiotherapy and has an inferior outcome compared with de novo myelodysplastic syndrome (de novo MDS). This study aimed to estimate and compare the clinical outcomes of haploidentical stem cell transplantation (haplo-HSCT) for t-MDS and de novo MDS. We retrospectively analyzed 96 patients with MDS who received haplo-HSCT between January 2015 and December 2021. Eleven patients with t-MDS and 85 patients with de novo MDS were matched using the case-pair method in a 1:8 ratio with the following pairing criteria: (1) sex, (2) age (± 5 years), (3) year of haplo-HSCT (± 2 years), and (4) blast cell counts (≥ 5% or not). The 3-year overall survival and disease-free survival after haplo-HSCT for t-MDS versus de novo MDS patients were 72.7% versus 75.1% (P = 0.99) and 54.5% versus 67.0% (P = 0.50), respectively. The 3-year cumulative incidence of relapse was 36.4% versus 15.5% (P = 0.08), respectively. In multivariate analysis, there was no difference in relapse between t-MDS and de novo MDS. The 3-year cumulative non-relapse mortality rates were 9.1% versus 17.6% (P = 0.45), respectively. This study confirmed the comparable clinical outcomes of haplo-HSCT on the prognosis of t-MDS and de novo MDS.

show abstract

Outcome of therapy‐related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis

Cited by 6 publications

References 53 publications

Allogeneic stem cell transplantation for patients with myelodysplastic syndromes

Allogeneic stem cell transplantation for patients with myelodysplastic syndromes

Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical relatives in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia: a propensity score analysis of a nationwide database

The clinical outcomes of haploidentical stem cell transplantation (haplo-HSCT) for patients with therapy-related myelodysplastic syndrome: comparable to de novo myelodysplastic syndrome

Contact Info

Product

Resources

About